Lawsuit-laden J&J recalls baby powder after asbestos alertJohnson & Johnson has said it is recalling around 33,000 bottles of baby powder in the US, after Share XLawsuit-laden J&J recalls baby powder after asbestos alerthttps://pharmaphorum.com/news/lawsuit-laden-jj-recalls-baby-powder-after-asbestos-alert/
J&J brushes off concerns over talc, opioid and Risperdal litigationJohnson & Johnson has brushed off investors’ concerns over the many lawsuits it is facing, saying its legal Share XJ&J brushes off concerns over talc, opioid and Risperdal litigationhttps://pharmaphorum.com/news/jj-brushes-off-concerns-over-litigation/
US court tells J&J to pay $8bn damages to man over breast growthA court has told Johnson & Johnson to pay $8 billion in punitive damages to a man who Share XUS court tells J&J to pay $8bn damages to man over breast growthhttps://pharmaphorum.com/news/us-court-tells-jj-to-pay-8bn-damages-to-man-over-breast-growth/
Drug firms colluded to hike essential medicine price by 1,800%, says UK watchdogThe UK’s competition watchdog has provisionally found three drug firms signed an illegal agreement, resulting in huge price Share XDrug firms colluded to hike essential medicine price by 1,800%, says UK watchdoghttps://pharmaphorum.com/news/drug-firms-colluded-to-hike-essential-medicine-price-by-1800-says-uk-watchdog/
France’s Servier finally goes on trial over Mediator safety scandalMore than a decade after a scandal over drug safety in France first broke, the pharma company Servier Share XFrance’s Servier finally goes on trial over Mediator safety scandalhttps://pharmaphorum.com/news/frances-servier-finally-goes-on-trial-over-mediator-safety-scandal/
Purdue preps bankruptcy as opioid settlement bid stumbles; reportPurdue Pharma is reported to be preparing to file for bankruptcy amid resistance to its $10-$12 billion offer Share XPurdue preps bankruptcy as opioid settlement bid stumbles; reporthttps://pharmaphorum.com/news/purdue-preps-bankruptcy-as-opioid-settlement-bid-stumbles-report/
Novo Nordisk faces $1.8 billion lawsuit over US insulin salesNovo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company Share XNovo Nordisk faces $1.8 billion lawsuit over US insulin saleshttps://pharmaphorum.com/news/novo-nordisk-faces-1-8-billion-lawsuit-over-us-insulin-sales/
Facing opioid liability risk, Mallinckrodt stalls generics splitMallinckrodt has put plans to separate its specialty generics business on hold while it gauges the impact of Share XFacing opioid liability risk, Mallinckrodt stalls generics splithttps://pharmaphorum.com/news/facing-opioid-liability-risk-mallinckrodt-stalls-generics-split/
German court blocks Sanofi’s cholesterol drug after Amgen lawsuitAmgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a Share XGerman court blocks Sanofi’s cholesterol drug after Amgen lawsuithttps://pharmaphorum.com/news/german-court-blocks-sanofis-cholesterol-drug-after-amgen-lawsuit/
